<DOC>
	<DOCNO>NCT01712854</DOCNO>
	<brief_summary>The purpose study investigate budesonide/formoterol fumarate dihydrate ( Symbicort Â© ) affect dynamic hyperinflation patient obstructive disease use Optoelectronic Plethysmography ( OEP ) . This study unique first randomize , doubleblind , crossover study placebo inhaler budesonide/formoterol fumarate dihydrate intervention evaluate effect ventilatory mechanic use OEP . The investigator plan demonstrate budesonide/formoterol fumarate dihydrate impact dynamic hyperinflation detect OEP , budesonide/formoterol fumarate dihydrate may effect short term exercise capacity constant load exercise test . The change ventilatory mechanic measure budesonide/formoterol fumarate dihydrate OEP provide unique evaluation budesonide/formoterol fumarate dihydrate control setting also demonstrate utility OEP evaluate effect medical treatment hyperinflation individual chronic obstructive lung disease ( COPD ) . 1 . Primary Objective/Hypothesis : Our objective measure baseline , post treatment post exercise spirometry evaluate exercise dynamic hyperinflation treatment use OEP . The investigator hypothesize budesonide/formoterol fumarate dihydrate decrease dynamic hyperinflation measure OEP . 2 . Primary Endpoint : Our primary endpoint change dynamic hyperinflation , specifically end expiratory volume , dynamic lung volume diaphragmatic paradoxical breathing measure OEP . 3 . Secondary Objective : Our secondary objective evaluate duration steady state exercise exercise capacity treatment . Our secondary hypothesis decrease dynamic hyperinflation exercise lead improvement dyspnea exercise , allow increase exercise capacity . 4 . Secondary endpoint : Exercise time , change Borg scale rest vs. Borg scale steady state vs. Borg end exercise .</brief_summary>
	<brief_title>Effects Symbicort Ventilatory Kinematics</brief_title>
	<detailed_description>This study prospective , randomize , double blind , crossover interventional design . The crossover allow equality number subject assign treatment subject control . Baseline spirometry take prior exercise test . Subjects prepared OEP . All exercise take place electromagnetically brake cycle ergometer . Throughout protocol heart rate , blood pressure , O2 saturation , ventilation , metabolic data record . A modified exercise induce asthma protocol use . Unlike prior study , ventilatory kinematics ( isolate diaphragmatic function ) monitor throughout exercise use biomechanical motion analysis ( OEP ) . This OEP analysis involve compartmentalization chest three section ; 1 ) pulmonary rib cage , 2 ) diaphragmatic rib cage , 3 ) abdomen determine contribution component total lung volume . By measure percent contribution compartment , able good understand impact respiration . OEP able quantify assess distortion effect dynamic hyperinflation obstruction . Twenty moderate severe COPD patient recruit . Subjects refrain usual inhaled medication 24 hour prior test session . All subject ask verify acceptable pulmonologist prior participation . Subjects also ask short act bronchodilator regular medication available take symptom occur . During initial screening , subject familiarize procedure . Then baseline pulmonary function testing , baseline rest OEP measurement perform . The subject randomize receive either budesonide/formoterol fumarate dihydrate ( Symbicort ) placebo budesonide ( Entocort EC ) . At time , receive treatment either placebo budesonide/formoterol fumarate dihydrate 45 minute , repeat spirometry OEP submaximal exercise test OEP . After one week , subject test switched opposite treatment ( i.e . budesonide/formoterol fumarate dihydrate initially switch placebo vice versa ) . The one week washout period test include resumption usual medication . The subject refrain inhaled medication 24 hour second test session , use usual medication .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<criteria>Moderate severe COPD Global Initiative Chronic Obstructive Lung Disease ( GOLD ) criterion Approval pulmonologist Informed consent Age 40 75 Males females All race Ex smoker non smoker Prior therapy allow No active cardiac disease Alpha1 Antitrypsin Deficiency Active smoke Reactive Airways Disease Pulmonary Hypertension Comorbid condition prevent exercise ( arthritic , neurologic , vascular , condition ) BMI &gt; 30 Current enrollment concurrent study Columbia University Medical Center sponsor AstraZeneca site Participation pharmacologic study last 6 month prior enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>Chronic Obstructive Lung Disease</keyword>
	<keyword>Long act beta agonist</keyword>
</DOC>